The Proteomics Facility provides a comprehensive suite of proteomics services to the Cancer Center membership. The primary emphasis is to provide expert consultation and state-of-the-art technologies operating at maximum performance at affordable costs to Cancer Center members. This is quite challenging because unlike genomics, proteomics technologies are highly varied;there are not consensus optimal approaches for most problems, and instruments, software and analytical strategies continue to evolve rapidly. Therefore, equipment and analytical methods must be continually updated. As a result, most of the instruments in the Facility were purchased within the past grant period, which includes $1.3 million invested in 2008 alone to replace obsolete mass spectrometers with 2 LTQ Orbitrap mass spectrometers and a high sensitivity triple quadropole mass spectrometer. Sensitivity of protein identifications has increased more than 100-fold over the past grant period through a combination of method optimization, acquisition of more sensitive instruments and development of an improved data analysis pipeline. Other methods have been similarly improved and new complementary methods have been implemented. The facility is also beginning to implement quantitative protein profile comparisons on LC-MS/MS based analyses using several complementary approaches, which will be expanded during the next grant period. During the past grant period (2003-present), 19 CC members used the Proteomics Facility and additional members benefited because many projects were collaborative between multiple CC investigators. CC members receive priority in sample analysis, substantial discounts on user fees (35-50% depending upon the service), more extensive consultation, training and assistance, and early access to methods/technologies not yet implemented as routine services. In the current year CCSG support covered 27% of non-equipment operating costs and will cover 23% of operating costs during the first year of the proposed grant. During 2007 44% of facility usage was by peer-reviewed CC members, and over the entire past grant period (2003-present) 61% of facility usage was by peer-reviewed CC members.
Proteomics can only be accomplished as a facility because of the expense of the instrumentation and expertise needed for their operation. Proteomics offer the hope of identifying biomarkers for the early detection of cancer.
|Qin, Jie; Rajaratnam, Rajathees; Feng, Li et al. (2015) Development of organometallic S6K1 inhibitors. J Med Chem 58:305-14|
|Tomescu, Costin; Seaton, Kelly E; Smith, Peter et al. (2015) Innate activation of MDC and NK cells in high-risk HIV-1-exposed seronegative IV-drug users who share needles when compared with low-risk nonsharing IV-drug user controls. J Acquir Immune Defic Syndr 68:264-73|
|Gekonge, Bethsebah; Bardin, Matthew C; Montaner, Luis J (2015) Short communication: Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages. AIDS Res Hum Retroviruses 31:237-41|
|Webster, Marie R; Xu, Mai; Kinzler, Kathryn A et al. (2015) Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell Melanoma Res 28:184-95|
|Zhang, Xuhui; Akech, Jacqueline; Browne, Gillian et al. (2015) Runx2-Smad signaling impacts the progression of tumor-induced bone disease. Int J Cancer 136:1321-32|
|Kung, Che-Pei; Khaku, Sakina; Jennis, Matthew et al. (2015) Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol Cancer Res 13:250-62|
|Wolf, Amaya I; Strauman, Maura C; Mozdzanowska, Krystyna et al. (2014) Pneumolysin expression by streptococcus pneumoniae protects colonized mice from influenza virus-induced disease. Virology 462-463:254-65|
|Gumireddy, Kiranmai; Li, Anping; Kossenkov, Andrew V et al. (2014) ID1 promotes breast cancer metastasis by S100A9 regulation. Mol Cancer Res 12:1334-43|
|Budina-Kolomets, Anna; Balaburski, Gregor M; Bondar, Anastasia et al. (2014) Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and HSP90 inhibition. Cancer Biol Ther 15:194-9|
|Newhart, Alyshia; Janicki, Susan M (2014) Seeing is believing: visualizing transcriptional dynamics in single cells. J Cell Physiol 229:259-65|
Showing the most recent 10 out of 182 publications